Pharmaceutical

XKDCT-080 by Guangdong Xiankangda Biotechnology for Colorectal Cancer: Likelihood of Approval

XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and currently in Phase II for Colorectal Cancer.

Jul 1, 2023 - 20:00
XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and currently in Phase II for Colorectal Cancer.
Read the original article

Tags:

Previous Article

Cold agglutinin disease by NovelMed Therapeutics for Acquired (Autoimmune) Hemol...

Next Article

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

Top 20 biopharma kick off 9.6% market cap surge in Q1 2...

Apr 27, 2024

STAT+: Ventyx stock craters after lackluster mid-stage trial results for psoriasis drug

STAT+: Ventyx stock craters after lackluster mid-stage ...

Nov 7, 2023

STAT+: Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole

STAT+: Roivant’s CEO is a star, but even a blockbuster ...

Oct 24, 2023